Description

Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8[1][2][3].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Gazzah A, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.|[2]Lorenzo Belluomini, et al. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. Cancers (Basel). 2023 Nov 10;15(22):5368. |[3]Ye-Jin Kim, et al. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Front Oncol. 2023 Feb 27:13:1124039. -CASNumber-2254086-60-5-MolecularWeight-148000 (average)-Compound Purity-99.42-SMILES-[Tusamitamab ravtansine]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);Microtubule/Tubulin-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related